Priothera
  • Home
  • Science
    • Mocravimod
    • Acute Myeloid Leukemia & Hematopoietic Cell Transplantation
    • CAR T Cells
    • Our Pipeline
    • Publications
  • MO-TRANS
  • Press
  • About
    • Our Leadership Team
    • Advisory Board
    • Investors
    • Our Partners
    • ESG and Recognition
  • Contact
Select Page

A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics and efficacy of KRP203 in subjects undergoing allogeneic hematopoietic cell transplantation for hematological malignancies

https://priotherabk.raredev.co.uk/a-two-part-single-and-two-arm-randomized-open-label-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-and-efficacy-of-krp203-in-subjects-undergoing-allogeneic-hematopoietic-cell-trans/

A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis

https://priotherabk.raredev.co.uk/a-multicentre-double-blind-placebo-controlled-parallel-group-study-to-evaluate-the-efficacy-safety-and-tolerability-of-the-s1p-receptor-agonist-krp203-in-patients-with-moderately-active-refractor/

S1P Receptor-1 agnoist averts the de novo generation of autoreactive T cells in murine acute GvHD

https://priotherabk.raredev.co.uk/s1p-receptor-1-agnoist-averts-the-de-novo-generation-of-autoreactive-t-cells-in-murine-acute-gvhd/

Short-term KRP203 and post-transplant cyclophosphamide for graft-versus-host disease prophylaxis

https://priotherabk.raredev.co.uk/short-term-krp203-and-post-transplant-cyclophosphamide-for-graft-versus-host-disease-prophylaxis/

GvHD prophylaxis with KRP203, a sphingosine-1-phosphate receptor modulator, is safe and may have the potential to improve survival in patients undergoing allogeneic stem cell transplantation

https://priotherabk.raredev.co.uk/gvhd-prophylaxis-with-krp203-a-sphingosine-1-phosphate-receptor-modulator-is-safe-and-may-have-the-potential-to-improve-survival-in-patients-undergoing-allogeneic-stem-cell-transplantation/

The role of S1P receptor-1 agonism in thymus-dependent T cell regeneration and graft-versus-tumor activity following experimental allogeneic hematopoietic cell transplantation

https://priotherabk.raredev.co.uk/the-role-of-s1p-receptor-1-agonism-in-thymus-dependent-t-cell-regeneration-and-graft-vs-tumor-activity-following-experimental-allogeneic-hematopoietic-cell-transplantation/
« Older Entries
Next Entries »

Recent Posts

  • PRIOTHERA révolutionne le standard des soins dans les thérapies cellulaires en hémato-oncologie
  • Cancer : Priothera veut limiter les risques des greffes de cellules souches
  • Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
  • LMA : Phase III et levée de fonds en cours pour Priothera
  • Booster l’efficacité des thérapies cellulaires

Recent Comments

  • Priothera to start Phase IIb/III trial of acute myeloid leukaemia therapy on Priothera Receives FDA clearance of Investigational New Drug (IND)
  • FDA grants orphan drug designation to mocravimod for acute myeloid leukemia - Healio - The Online Chemists on Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

Priothera, Adding Quality Years to Life

Get In Touch

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

© Priothera Ltd. 2025

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland